Ken Griffin Regenxbio Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.49 - $14.39 $12,588 - $17,268	1,200 Added 6.59%	19,400 $203,000
Q2 2024 Aug 14, 2024	SELL	$11.51 - $21.53 $49,493 - $92,579	-4,300 Reduced 19.11%	18,200 $212,000
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $74,237 - $150,121	6,100 Added 37.2%	22,500 $474,000
Q4 2023 Feb 14, 2024	SELL	$12.89 - $20.82 $25,780 - $41,640	-2,000 Reduced 10.87%	16,400 $294,000
Q3 2023 Nov 14, 2023	SELL	$16.46 - $19.99 $77,362 - $93,952	-4,700 Reduced 20.35%	18,400 $302,000
Q2 2023 Aug 14, 2023	BUY	$17.23 - $21.71 $149,901 - $188,877	8,700 Added 60.42%	23,100 $461,000
Q1 2023 May 15, 2023	BUY	$18.08 - $24.55 $106,671 - $144,845	5,900 Added 69.41%	14,400 $272,000
Q4 2022 Feb 14, 2023	SELL	$20.4 - $24.73 $108,119 - $131,069	-5,300 Reduced 38.41%	8,500 $192,000
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $46,809 - $73,584	-2,100 Reduced 13.21%	13,800 $365,000

197

43.2M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $433M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.